title: [Mesenchymal stromal cells in the treatment of graft-versus-host disease: where do we stand?].
abstract: Medicinal products based on mesenchymal stromal cells (MSC) are expected to have a therapeutic benefit in a variety of conditions and, accordingly, are being tested in many clinical studies. The treatment and prevention of graft-versus-host disease (GVHD) is one of the world's most widely studied MSC therapy concepts. So far, one MSC medicinal product has been approved for the treatment of GvHD. This article gives an overview of the particular features related to the production of MSC-based medicinal products, the state of non-clinical research, and the clinical development status of MSCs and the associated challenges, especially in the context of GvHD.
authors.affiliation: Abteilung Medizinische Biotechnologie, Fachgebiet Arzneimittel für neuartige Therapien Gewebezubereitungen, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland. Silke.Schuele@pei.de.
authors.forename: Silke
authors.initials: S
authors.lastname: Schüle
authors.affiliation: Abteilung Medizinische Biotechnologie, Fachgebiet Arzneimittel für neuartige Therapien Gewebezubereitungen, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland. Andre.Berger@pei.de.
authors.forename: André
authors.initials: A
authors.lastname: Berger
mesh_terms: D002986:Clinical Trials as Topic; D006086:Graft vs Host Disease / Q000628:therapy*; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D035703:Therapies, Investigational / Q000379:methods*; D016896:Treatment Outcome
keywords: ATMP; Advance Therapy Medicinal Products; Cell-based Medicinal Products; Graft versus host disease; Mesenchymal stem cells; Mesenchymal stroma cells